NEW DELHI: In a major move, the Serum Institute of India (SII) has reduced the price of its COVID-19 vaccine ‘Covishield’ from Rs 400 to Rs 300 per dose for states, announced firm CEO Adar Poonawallah on Wednesday.
“As a philanthropic gesture on behalf of Serum Institute of India, I hereby reduce the price to the states from Rs 400 to Rs 300 per dose, effective immediately; this will save thousands of crores of state funds going forward. This will enable more vaccinations and save countless lives,” Poonawalla tweeted.
The SII manufactures the Covishield vaccine, while Bharat Biotech is the manufacturer of Covaxin.
Earlier this month, Adar Poonawalla, CEO of Serum Institute of India, had asked the government for financial assistance to ramp up vaccine production.
Recently, the Centre announced that everyone above the age of 18 will be eligible to get vaccinated against COVID-19 in the vaccination drive beginning May 1. Several important decisions were taken in a meeting chaired by Prime Minister Narendra Modi regarding pricing, procurement, eligibility and administration of vaccines being made flexible in Phase 3 of the world’s largest vaccination drive.